Bessemer Group Inc. Takes Position in Maze Therapeutics, Inc. (NASDAQ:MAZE)

Bessemer Group Inc. acquired a new stake in shares of Maze Therapeutics, Inc. (NASDAQ:MAZE - Free Report) during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 481,790 shares of the company's stock, valued at approximately $5,305,000. Bessemer Group Inc. owned 1.10% of Maze Therapeutics at the end of the most recent reporting period.

Separately, General Catalyst Group Management LLC acquired a new stake in Maze Therapeutics in the first quarter worth approximately $11,405,000.

Analyst Upgrades and Downgrades

Separately, Guggenheim reiterated a "buy" rating and set a $19.00 price target on shares of Maze Therapeutics in a research report on Wednesday, April 2nd. Three analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Buy" and an average price target of $25.67.

Maze Therapeutics Trading Down 4.8%

NASDAQ MAZE traded down $0.61 on Friday, reaching $12.13. The company's stock had a trading volume of 237,657 shares, compared to its average volume of 102,936. Maze Therapeutics, Inc. has a twelve month low of $6.71 and a twelve month high of $17.00. The business has a 50 day moving average price of $10.86.

Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last released its earnings results on Wednesday, May 14th. The company reported ($1.15) EPS for the quarter, missing analysts' consensus estimates of ($0.76) by ($0.39).

Maze Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.